HIV protease inhibition: Limited recent progress and advances in understanding current pitfalls

Current Topics in Medicinal Chemistry

Volumn 4, Issue 9, 2004, Pages 991-1007

  Rodríguez Barrios, Fátima ^a   Gago, Federico ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

A 74704; A 77003; AG 1776; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ASTEMIZOLE; ATAZANAVIR; EFAVIRENZ; ERGOT ALKALOID; FLUOXETINE; INDINAVIR; JE 2147; KETOCONAZOLE; L 756423; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LP 130; MK 944 A; NELFINAVIR; NEVIRAPINE; PEPTIDE HYDROLASE INHIBITOR; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TERFENADINE; TIPRANAVIR; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CHEMICAL REACTION KINETICS; CLINICAL TRIAL; DIABETIC KETOACIDOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; ENZYME ANALYSIS; ENZYME INHIBITOR INTERACTION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIPODYSTROPHY; NAUSEA; NEPHROLITHIASIS; NONHUMAN; PROTEINASE INHIBITION; QT PROLONGATION; REVIEW; STRUCTURE ANALYSIS; VOMITING; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2942534993     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043388529     Document Type: Review

References (115)

1. Frankel, A.D.; Young, J.A,T. HIV-1: Fifteen Proteins and an RNA. Annu. Rev. Biochem. 1998, 67, 1-25.
2. Huff, J. R. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
3. Wlodawer, A.; Erickson, J. W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 1993, 62, 543-585.
4. Gago, F. Targeting HIV-1 protease: from peptidomimetics to non-peptide inhibitors. IDrugs, 1999, 2, 309-320.
5. Tomasselli, A. G.; Heinrikson, R. L. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta 2000, 1477, 189-214.
6. Lebon, F.; Ledecq, M. Approaches to the Design of Effective HIV-1 Protease Inhibitors. Curr. Med. Chem. 2000, 7, 455-477.
7. Navia, M. A.; Fitzgerald, P. M.; McKeever, B. M., Leu, C. T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337, 615-620.
8. Lapatto, R.; Blundell, T.; Hemmings, A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, S. J.; Lee, S. E.; Scheld, K. G.; Hobart, P. M. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 1989, 342, 299-302.
9. Wlodawer, A.; Vondrasek, J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 249-284.
10. Vondrasek J, van Buskirk CP, Wlodawer A: Database of three-dimensional structures of HIV proteinases. Nat. Struct. Biol. 1997, 4, 8.
11. Bardi, J. S.; Luque, I.; Freire, E. Structure-based thermodynamic analysis of HIV-1 protease inhibitors. Biochemistry 1997, 36, 6588-6596.
12. Babine, R. E.; Bender, S. L. Molecular recognition of protein-ligand complexes: applications to drug design. Chem. Rev. 1997, 97, 1359-1472.
13. Österberg, F.; Morris, G. M.; Sanner, M. F.; Olson, A. J.; Goodsell, D. S. Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock. Proteins 2002, 46, 34-40.
14. Pastor, M.; Pérez, C.; Gago, F. Simulation of alternative binding modes in a structure-based QSAR study of HIV-1 protease inhibitors. J. Mol. Graph. Model. 1997, 15, 364-71, 389.
15. Pérez, C.; Ortiz, A. R.; Pastor, M.; Gago, F. Comparative Binding Energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design. J. Med. Chem. 1998, 41, 836-852.
16. Kulkarni, S. S.; Kulkarni, V. M. Structure based prediction of binding affinity of human immunodeficiency virus-1 protease inhibitors. J. Chem. Inf. Comput. Sci. 1999, 39, 1128-1140.
17. Vieth, M.; Cummins, D. J. DoMCoSAR: a novel approach for establishing the docking niode that is consistent widi the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2000, 43, 3020-3032.
18. Kalra, P.; Reddy, T. V.; Jayaram, B. Free energy component analysis for drug design: a case study of HIV-1 protease-inhibitor binding. J. Med. Chem. 2001, 44, 4325-4338.
19. Wang, W.; Kollman, P. A. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc. Natl. Acad. Sci. U S A 2001, 98, 14937-14942.
20. Nicholson, L. K.; Yamazaki, T.; Torchia, D. A.; Grzesiek, S.; Bax, A.; Stahl, S. J.; Kaufman, J. D.; Wingfield, P. T.; Lam, P. Y.; Jadhav, P. K.; Hodge, C. N.; Domaille, P. J.; Chang, C.-H. Flexibility and function in HIV-1 protease. Nat. Struct. Biol. 1995, 2, 274-280.
21. Smith, R.; Brereton, I. M.; Chai, R. Y.; Kent, S. B. Ionization states of the catalytic residues in HIV-1 protease. Nat. Struct. Biol. 1996, 3, 946-950.
22. Wlodawer, A.; Erickson, J. W. Structure-based inhibitors or HIV-1 protease. Annu. Rev. Biochem. 1993, 62, 543-585.
23. Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Kröhn, A. et al: Rational design of peptide-based HIV proteinase inhibitors. Science, 1990, 248, 358-361.
24. Krohn, A.; Redshaw, S.; Ritchie, J. C.; Graves, B. J.; Hatada, M.H. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 1991, 34, 3340-3342.
25. Holloway, M. K.; Wai, J. M.; Halgren, T. A.; Fitzgerald, P. M. D.; Vacca, J. P.; Dorsey, B. D.; Levin, R. B.; Thompson, W. J.; Chen, L. J.; deSolms, S. J.; Gaffin, N.; Ghosh, A. K.; Giuliani, E. A.; Graham, S. L.; Guare, J. P.; Hungate, R. W.; Lyle, T. A.; Sanders, W. M.; Tucker, T. J.; Wiggins, M.; Wiscount, C. M.; Woltersdorf, O. W.; Young, S. D.; Darke, P. L. & Zugay, J. A. A Priori Prediction of Activity for HIV-1 Protease Inhibitors Employing Energy Minimization in the Active Site. J. Med. Chem. 1995, 38, 305-317.
26. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E., et al: L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. U S A 1994, 91, 4096-4100.
27. Kempf, D. J.; Norbeck, D. W.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. F.; Paul, D. A.; Knigge, M. F.; Vasavanonda, S.; Craig-Kennard, A. C.; Saldivar, A.; Rosenbrook, W. Jr., Plattner, J. J.; Erickson, J.: Structure-based, C2 symmetric inhibitors of HIV protease. J. Med. Chem. 1990, 33, 2687-2689.
28. Erickson, J.; Neidhart, D. J.; VanDrie, J.; Kempf, D. J.; Wang, X. C.; Norbeck, D. W.; Plattner, J. J.; Rittenhouse, J. W.; Turon, M.; Wideburg, N.; Kohlbrenner, W. E.; Simmer, R.; Helfrich, R.; Paul, D. A.; Knigge, M. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 249, 527-533.
29. Dreyer, G. B.; Boehm, J. C.; Chenera, B.; DesJarlais, R. L.; Hassell, A. M.; Meek, T. D.; Tomaszek, T. A. Jr, Lewis, M. A symmetric inhibitor binds HIV-1 protease asymmetrically. Biochemistry 1993, 32, 937-947.
30. Kempf, D. J.; Sham, H. L.; Marsh, K. C.; Flentge, C. A.; Betebenner, D.; Green, B. E.; McDonald, E.; Vasavanonda, S.; Saldivar, A.; Wideburg, N. E.; Kati, W. M.; Ruiz, L.; Zhao, C.; Fino, L.; Patterson, J.; Molla, A.; Plattner, J. J.; Norbeck, D. W. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J. Med. Chem. 1998, 41, 602-617.
31. Sham, H. L.; Kempf, D. J.; Molla, A.; Marsh, K. C.; Kumar, G. N.; Chen, C. M.; Kati, W.; Stewart, K,; Lal, R.; Hsu, A.; Betebenner, D.; Korneyeva, M.; Vasavanonda, S.; McDonald, E.; Saldivar, A.; Wideburg, N.; Chen, X.; Niu, P.; Park, C.; Jayanti, V.; Grabowski, B.; Granneman, G. R.; Sun, E.; Japour, A. J.; John, M.; Leonard, J. M.; Plattner, J. J.; Norbeck, D. W. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.
32. Stoll, V.; Qin, W.; Stewart, K. D.; Jakob, C.; Park, C.; Walter, K.; Simmer, R. L.; Helfrich, R.; Bussiere, D.; Kao, J.; Kempf, D.; Sham, H. L.; Norbeck, D. W. X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease. Bioorg. Med. Chem. 2002, 10, 2803-2806.
33. Kaldor, S. W.; Kalish, V. J.; Davies, J. F. 2nd; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 1997, 40, 3979-3985.
34. Kim, E. E.; Baker, C. T.; Dwyer, M. D.; Murcko, M. A.; Rao, B. G.; Tung, R. D.; Navia, M. A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 1995, 117, 1181-1182.
35. Roberts, J. D.; Bebenek, K.; Kunkel, T. A. The accuracy of reverse transcriptase from HIV-1. Science 1988, 242, 1171-1173.
36. Tisdale, M.; Myers, R. E.; Maschera, B.; Parry, N. R.; Oliver, N. M.; Blair, E. D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 1995, 39, 1704-1710.
37. Jacobsen, H.; Yasargil, K.; Winslow, D. L.; Craig, J. C.; Kröhn, A.; Duncan, I. B.; Mous, J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995, 206, 527-534.
38. Pazhanisamy, S.; Partaledis, J. A.; Rao, B. G.; Livingston, D. J. In vitro selection and characterization of VX-478 resistant HIV-1 variants. Adv. Exp. Med. Biol. 1998, 436, 75-83.
39. Condra, J. H.; Holder, D. J.; Schleit, W. A.; Blahy, O. M.; Danovich, R. M.; Gabryelski, L. J.; Graham, D. J.; Laird, D.; Quintero, J. C.; Rhodes, A.; Robbins, H. L.; Roth, E.; Shivaprakash, M.; Yang, T.; Chodakewitz, J. A.; Deutsch, P. J.; Leavitt, R. Y.; Massari, F. E.; Mellors, J. W.; Squires, K. E.; Steigbigel, R. T.; Teppler, H.; Emini, E. A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 1996, 70, 8270-8276.
40. Markowitz, M. M.; Mo, H.; Kempf, D. J.; Norbeck, D. W.; Bhat, T. N.; Erickson, J. W.; Ho, D. D. Selection and analysis of HIV-1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 1995, 69, 701-706.
41. Bardsley-Elliot, A.; Plosker, G. L. Nelfinavir: an update on its use in HIV infection. Drugs 2000, 59, 581-620.
42. Patick, A. K.; Mo, H.; Markowitz, M.; Appelt, K.; Wu, B.; Musick, L.; Kalish, V.; Kaldor, S.; Reich, S.; Ho, D.; Webber, S. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 1996, 40, 292-297. D35N → D30N erratum published in ibid. 1996, 40, 1575.
43. Olsen, D. B.; Stahlhut, M. W.; Rutkowski, C. A.; Schock, H. B.; van Olden, A. L.; and Kuo, L. C. J. Biol. Chem. 1999, 274, 23699-23701.
44. Muzammil, S.; Ross, P.; Freire, E. A Major Role for a Set of Non-Active Site Mutations in the Development of HIV-1 Protease Drug Resistance. Biochemistry 2003, 42, 631-638.
45. Hammond, J.; Larder, B. A.; Mellors, J. W.; Schinazi, R. F. The HIV Drug Resistance Database, HIV database group, Theoretical Biology and Biophysics Division, Los Alamos National Laboratory.
46. Lech, W. J.; Wang, G.; Yang, Y. L.; Chee, Y.; Dorman, K.; McCrae, D.; Lazzeroni, L. C.; Erickson, J. W.; Sinsheimer, J. S.; Kaplan, A. H. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. Virol. 1996, 70, 2038-2043.
47. Molla, A.; Korneyeva, M.; Gao, Q.; Vasavanonda, S.; Schipper, P. J.; Mo, H. M.; Markowitz, M.; Chernyavskiy, T.; Niu, P.; Lyons, N.; Hsu, A.; Granneman, G. R.; Ho, D. D.; Boucher, C. A.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 1996, 2, 760-766.
48. Watkins, T.; Resch, W.; Irlbeck, D.; Swanstrom, R. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 2003, 47, 759-769.
49. Klabe, R. M.; Bacheler, L. T.; Ala, P. J.; Erickson-Viitanen, S.; Meek, J. L. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 1998, 37, 8735-8742.
50. Carrillo, A.; Stewart, K. D.; Sham, H. L.; Norbeck, D. W.; Kohlbrenner, W. E.; Leonard, J. M.; Kempf, D. J.; Molla, A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 1998, 72, 7532-7541.
51. Molla, A.; Vasavanonda, S.; Kumar, G.; Sham, H. L.; Johnson, M.; Grabowski, B.; Denissen, J. F.; Kohlbrenner, W.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W.; Kempf, D. J. Human serum attenuates the activity of protease inhibitor toward wild-type and mutant human immunodeficiency virus. Virology 1998, 250, 255-262.
52. Flexner, C. HIV-protease inhibitors. N. Engl. J. Med. 1998, 338, 1281-1292.
53. von Moltke, L. L.; Greenblatt, D. J.; Grassi, J. M.; Granda, B. W.; Duan, S. X.; Fogelman, S. M.; Daily, J. P.; Harmatz, J. S.; Shader, R. I. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 1998, 38, 106-111.
54. Condra, J. H.; Petropoulos, C. J.; Ziermann R.; Schleif W. A.; Shivaprakash M.; Emini E. A. Drug resistance and predicted virologic response to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 2000, 182, 758-765.
55. Luo, G.; Cunningham, M.; Kim, S.; Burn, T.; Lin, J.; Sinz, M.; Hamilton, G.; Rizzo, C.; Jolley, S.; Gilbert, D.; Downey, A.; Mudra, D.; Graham, R.; Carroll, K.; Xie, J.; Madan, A.; Parkinson, A.; Christ, D.; Selling, H.; LeCluyse, E.; Gan, L. S. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 2002, 30, 795-804.
56. Riddle, F. M.; Kuhel, D. G.; Woollett, L A.; Fichtenbaum, C. J.; Hui, D. Y. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 2001, 270, 37514-37519.
57. Carpenter, C. C.; Fischl, M. A.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280, 78-86.
58. Molla, A.; Mo, H.; Vasavanonda, S.; Han, L.; Lin, C. T.; Hsu, A.; Kempf, D. J. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob. Agents Chemother. 2002, 46, 2249-2253.
59. Panel on Clinical Practices for Treatment of HIV Infection: Guidelines for the Use of Antiretroviral Agents in HIV-Infected Pediatrics/Adults and Adolescents. AIDSinfo (2002).
60. Falcoz, C.; Jenkins, J. M.; Bye, C.; Hardman, T. C.; Kenney, K. B.; Studenberg, S.; Fuder, H.; Prince, W. T. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 2002, 42, 887-898.
61. De Bethune M et al. TMC114, a highly potent protease inhibitor with an excellent profile against HIV variants highly resistant to current Pls. 41st Interscience Conference on Antimicrobial and Antiviral Chemotherapy, Chicago, abstract F-1677, 2001.
62. Graham, N. TMC-114: a novel protease inhibitor. Eighth Annual Conference of the British HIV Association, York, 2002.
63. De Meyer, S.; Azijn, H.; van Ginderen, M.; De Baere, I.; Pauwels, R.; de Béthune, M.-P. In vitro selection experiments demonstrate an increased genetic barrier to resistance development to TMC114 as compared with currently licensed protease inhibitors. XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Seville, abstract S5, 2002.
64. Ghosh, A. K.; Pretzer, E.; Cho, H.; Hussain, K. A.; Duzgunes, N. Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. Antiviral Res. 2002, 54, 29-36.
65. Yoshimura, K.; Kato, R.; Kavlick, M. F.; Nguyen, A.; Maroun, V.; Maeda, K.; Hussain, K. A.; Ghosh, A. K.; Gulnik, S. V.; Erickson, J. W.; Mitsuya, H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 2002, 70, 1349-1358
66. Fischl, M. A.; Richman, D. D.; Flexner, C.; Para, M. F.; Haubrich, R.; Karim, A.; Yeraman, P.; Holden-Wiltse, J.; Meehan, P. M. Phase I study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 15, 28-34.
67. Kaltenbach III, R. F.; Trainor, G.; Getman, D.; Harris, G.; Garber, S.; Cordova, B.; Bacheler, L.; Jeffrey, S.; Logue, K.; Cawood, P.; Klabe, R.; Diamond, S.; Davies, M.; Saye, J.; Jona, J.; Erickson-Viitanen, S. DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants. Antimicrob. Agents Chemother. 2001, 45, 3021-3028.
68. Jungheim, L. N.; Shepherd, T.A.; Baxter, A.J.; Burgess, J.; Hatch, S. D.; Lubbehusen, P.; Wiskerchen, M.; Muesing, M. A. Potent Human Immunodeficiency Virus Type 1 Protease Inhibitors That Utilize Noncoded D-Amino Acids as P2/P3 Ligands. J. Med. Chem. 1996, 39, 96-108.
69. Tamamura, H.; Koh, Y.; Ueda, S.; Sasaki, Y.; Yamasaki, T.; Aoki, M.; Maeda, K.; Watai, Y.; Arikuni, H.; Otaka, A.; Mitsuya, H.; Fujii, N. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against mutidrug resistant HIV-1 strains. J. Med. Chem. 2003, 46, 1764-1768.
70. Dorsey, D. D.; McDonough, C.; McDaniel, S. L.; Levin, R. B.; Newton, C. L.; Hoffman, J. M.; Darke, P. L.; Zugay-Murphy, J. A.; Emini, E. A.; Schleif, W. A.; Olsen, D. B.; Stahlhut, M. W.; Rutkowski, C. A.; Kuo, L. C., Lin, J. H.; Chen, I. W.; Michelson, S. R.; Holloway, M. K.; Huff, J. R.; Vacca, J. P. Identification of MK-944a: A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors. J. Med. Chem. 2000, 43, 3386-3399.
71. Kiso, Y. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere. Biopolymers 1996, 40, 235-244.
72. Yoshimura, K.; Kato, R.; Yusa, K.; Kavlick, M. F.; Maroun, V.; Nguyen, A.; Mimoto, T.; Ueno, T.; Shintani, M.; Falloon, J.; Masur, H.; Hayashi, H.; Erickson, J.; Mitsuya, H. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. US.A. 1999, 96, 8675-8680.
73. Reiling, K. K.; Endres, N. F.; Dauber, D. S; Craik, C. S.; Stroud, R. M. Anisotropic Dynamics of the JE-2147-HIV Protease Complex: Drug Resistance and Thermodynamic Binding Mode Examined in a 1.09 Å Structure. Biochemistry 2002, 41, 4582-4594.
74. Kervinen, J.; Lubkowski, J.; Zdanov, A.; Bhatt, D.; Dunn, B. M.; Hui, K. Y.; Powell, D. J.; Kay, J.; Wlodawer, A.; Gustchina, A. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1 FIV, and EIAV. Protein Sci. 1998, 7, 2314-2323.
75. Weber, J.; Majer, P.; Litera, J.; Urban, J.; Soucek, M.; Vondrasek, J.; Konvalinka, J.; Novek, P.; Sedlacek, J.; Strop, P.; Krausslich, H. G.; Pichova, I. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2-proteinases: design of equipotent lead compounds. Arch. Biochem. Biophys. 1997, 341, 62-69.
76. Weber, J.; Mesters, J. R.; Lepsik, M.; Prejdova, J.; Svec, M.; Sponarova, J.; Mlcochova, P.; Skalicka, K.; Strisovskv, K.; ? Klimkova, T.; Soucek, M.; Machala, L.; Stankova, M.; Vondrasek, ? Klimkait, T.; Kraeusslich, H. G.; Hilgenfeld, R.; Konvalinka, J. Unusual Binding Mode of an HIV-1 Protease Inhibitor Explains its Potency against Multi-drug-resistant Virus Strains. J. Mol. Biol. ?02, 324, 739-754
77. Bourinbaiar, A. S.; Tan, X.; Nagorny, R. Effect of the oral anticoagulant, warfarin, on HIV-1 replication and spread. AIDS 1993, 7, 129-130.
78. Thaisrivongs, S.; Tomich, P. K.; Watenpaugh, K. D.; Chong, K. T.; Howe, W. J.; Yang, C. P.; Strohbach, J. W.; Turner, S. R.; McGrath, J. P.; Bohanon, M. J. et al: Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 1994, 37, 3200-3204.
79. Lunney, E. A.; Hagen, S. E.; Domagala, J. M.; Humblet, C.; Kosinski, J.; Tait, B. D.; Warmus, J. S.; Wilson, M.; Ferguson, D.; Hupe, D. et al: A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. J. Med. Chem. 1994, 37, 2664-2677.
80. Tait, B. D.; Hagen, S.; Domagala, J.; Ellsworth, E. L.; Gajda, C.; Hamilton, H. W.; Prasad, J. V.; Ferguson, D.; Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, J.; Gracheck, S. J.; Baldwin, E. T.; Bhat, T. N.; Erickson, J. W.; Gulnik, S. V.; Liu, B. Potent non-peptide inhibitors of HIV protease. J. Med. Chem. 1997, 40, 3781-3792.
81. Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M. M.; Lynn, J. C.; Chong, K. T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 1998, 41, 3467-3476.
82. Thaisrivongs, S.; Strohbach, J. W. Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers. 1999, 51, 51-58.
83. Larder, B. A.; Hertogs, K.; Bloor, S.; van den Eynde, C. H.; DeCian, W.; Wang, Y.; Freimuth, W. W.; Tarpley, G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000, 14, 1943-1948.
84. Lam, P. Y.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N. et al: Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994, 263, 380-384.
85. Lam, P. Y.; Ru, Y.; Jadhav, P. K.; Aldrich, P. E.; DeLucca, G. V.; Eyermann, C. J.; Chang, C. H.; Emmett, G.; Holler, E. R.; Daneker, W. F.; Li, L.; Confalone, P. N.; McHugh, R. J.; Han, Q.; Li, R.; Markwalder, J. A.; Seitz, S. P.; Sharpe, T. R.; Bacheler, L. T.; Rayner, M. M.; Klabe, R. M.; Shum, L.; Winslow, D. L.; Kornhauser, D. M.; Jackson, D. A.; Erickson-Viitanen, S.; Hodge, C. N. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J. Med. Chem. 1996, 39, 3514-3525.
86. Kaltenbach, R. F. III, Nugiel, D. A.; Lam, P. Y. S., Klabe, R. M.; Seitz, S. P. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities J. Med. Chem. 1998, 41, 5113-5117.
87. Wang, Y. X.; Freedberg, D. I.; Grzesiek, S.; Torchia, D. A.; Wingfield, P. T.; Kaufman, J. D.; Stahl, S. J.; Chang, C. H.; Hodge, C. N. Mapping hydration water molecules in the HIV-1 protease/DMP323 complex in solution by NMR spectroscopy. Biochemistry 1996, 35, 12694-12704.
88. Hodge, C. N.; Aldrich, P. E.; Bacheler, L. T.; Chang, C. H.; Eyermann, C. J.; Garber, S.; Grubb, M.; Jackson, D. A.; Jadhav, P. K.; Korant, B.; Lam, P. Y.; Maurin, M. B.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Reid, C.; Sharpe, T. R.; Shum, L.; Winslow, D. L.; Erickson-Viitanen, S. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol (1996) 3:301-314.
89. Nillroth, U.; Vrang, L.; Markgren, P. O.; Hultén, J.; Hallberg, A.; Danielson, U. H. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. Antimicrob. Agents Chemother. 1997, 41, 2383-2388.
90. Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C. H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. J. Med. Chem. 1997, 40, 181-191.
91. De Lucca, G. V., Liang, J., Aldrich, P. E.; Calabrese, J.; Cordova, B.; Klabe, R. M.; Rayner, M. M.; Chang, C. H. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors. J. Med. Chem. 1997, 40, 1707-1709.
92. Bäckbro, K.; Löwgren, S.; Osterlund, K.; Atepo, J.; Unge, T.; Hultén, J.; Bonham, N. M.; Schaal, W.; Karlén, A.; Hallberg, A. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J. Med. Chem. 1997, 40, 898-902.
93. Kim, C. U.; McGee, L. R.; Krawczyk, S. H.; Harwood, E.; Harada, Y.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Cherrington, J. M.; Xiong, S. F.; Griffin, L.; Cundy, K. C.; Lee, A.; Yu, B.; Gulnik, S.; Erickson, J. W. New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors. J. Med. Chem. 1996, 39, 3431-3434.
94. Jadhav, P. K.; Woerner, F. J.; Lam, P. Y.; Hodge, C. N.; Eyermann, C. J.; Man, H. W.; Daneker, W. F.; Bacheler, L. T.; Rayner, M. M.; Meek, J. L.; Erickson-Viitanen, S.; Jackson, D. A.; Calabrese, J. C.; Schadt, M.; Chang, C. H. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies. J. Med. Chem. 1998, 41, 1446-1455.
95. Skulnick, H. I.; Johnson, P. D.; Aristoff, P. A.; Morris, J. K.; Lovasz, K. D.; Howe, W. J.; Watenpaugh, K. D.; Janakiraman, M. N.; Anderson, D. J.; Reischer, R. J.; Schwartz, T. M.; Banitt, L. S.; Tomich, P. K.; Lynn, J. C.; Horng, M. M.; Chong, K. T.; Hinshaw, R. R.; Dolak, L. A.; Seest, E. P.; Schwende, F. J.; Rush, B. D.; Howard, G. M.; Toth, L. N.; Wilkinson, K. R.; Romines, K. R.; et al: Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyranones. J. Med. Chem. 1997, 40, 1149-1164.
96. Gante J. Azapeptides, a novel class of peptide analogs. Angew. Chem. Int. Ed. Engl. 1970, 9, 813.
97. Bold, G.; Fassler, A.; Capraro, H. G.; Cozens, R.; Klimkait, T.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rösel, J.; Stover, D.; Tintelnot-Blomley, M.; Acemoglu, F.; Beck, W.; Boss, E.; Eschbach, M.; Hürlimann, T.; Masso, E.; Roussel, S.; Ucci-Stoll, K.; Wyss, D.; Lang, M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J. Med. Chem. 1998, 41, 3387-3401.
98. Robinson, B. S.; Riccardi, K. A.; Gong, Y. F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Deminie, C. A.; Djang, F.; Colonno, R. J.; Lin, P. F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 2000, 44, 2093-2099.
99. Gong, Y. F.; Robinson, B. S.; Rose, R. E.; Deminie, C.; Spicer, T. P.; Stock, D.; Colonno, R. J.; Lin, P. F. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 2000, 44, 2319-2326.
100. Smidt, M. L.; Potts, K. E.; Tucker, S. P.; Blystone, L.; Stiebel, T. R. Jr, Stallings, W. C.; McDonald, J. J.; Pillay, D.; Richman, D. D.; Bryant, M. L. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob. Agents Chemother. 1997, 41, 515-522.
101. Colonno, R. J.; Friborg, J.; Rose, R. E.; Lam, E.; Parkin, N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir-containing regimens. XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Seville, abstract S4, 2002.
102. Sanne, I.; Piliero, P.; Squires, K.; Thiry, A.; Schnittman, S. Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects. J. Acquir. Immune. Defic. Syndr. 2003, 32, 18-29.
103. Rose, R. B.; Craik, C. S.; Stroud, R. M. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 1998, 37, 2607-2621.
104. Velazquez-Campoy, A.; Kiso, Y.; Freire, E. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 2001, 390, 169-175.
105. Ohtaka, H.; Velazquez-Campoy, A.; Xie, D.; Freire, E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 2002, 11, 1908-1916.
106. Markgren, P.-O.; Hämäläinen, M.; Danielson, U. H. Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology. Anal. Biochem. 2000, 279, 71-78.
107. Markgren, P. O.; Schaal, W.; Hämäläinen, M.; Karlén, A.; Hallberg, A.; Samuelsson, B.; Danielson, U. H. Relationships between Structure and Interaction Kinetics for HIV-1 Protease Inhibitors. J. Med. Chem. 2002, 45, 5430-5439.
108. Schramm, H. J.; Nakashima, H.; Schramm, W.; Wakayama, H.; Yamamoto, N. HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochem. Biophys. Res. Commun. 1991, 179, 847-851.
109. Zhang, Z.; Poorman, R.; Maggiora, L.; Heinrikson, R.; Kezdy, F. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 1991, 266, 15591-15594.
110. Sluis-Cremer, N.; Tachedjian, G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 2002, 269, 5103-5111.
111. Babé, L. M. ; Rose, J.; Craik, C. S. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci. 1992, 1, 1244-1253.
112. Zutshi, R.; Franciskovich, J.; Shultz, M.; Schweitzer, B.; Bishop, P.; Wilson, M.; Chmielewski, J. Targeting the Dimerization Interface of HIV-1 Protease: Inhibition with Cross-Linked Interfacial Peptides. J. Am. Chem. Soc. 1997, 119, 4841-4845.
113. Park, S.H.; Raines, R. T. Genetic selection for dissociative inhibitors of designated protein-protein interactions. Nat. Biotechnol. 2000, 18, 847-851.
114. Fan, X.; Flentke, G. R.; Rich, D. H. Inhibition of HIV-1 Protease by a subunit of didemnaketal A. J. Am. Chem. Soc. 1998, 120, 8893-8894.
115. Chun, T. W.; Carruth, L.; Finzi, D.; Shen, X.; DiGiuseppe, J. A.; Taylor, H.; Hermankova, M.; Chadwick, K.; Margolick, J.; Quinn, T. C.; Kuo, Y. H.; Brookmeyer, R.; Zeiger, M. A.; Barditch-Crovo, P.; Siliciano, R. F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387, 183-188.